NCT03365921View on ClinicalTrials.gov

A Phase Ⅳ Clinical Trial of the Recombinant Hepatitis E Vaccine (Escherichia Coli)(the Lot Consistency Trial)

PHASE4CompletedINTERVENTIONAL
Enrollment

360

Participants

Timeline

Start Date

October 27, 2018

Primary Completion Date

June 16, 2019

Study Completion Date

June 16, 2019

Conditions
Hepatitis E
Interventions
BIOLOGICAL

Participants would receive 3 doses of Recombinant Hepatitis E Vaccine (Escherichia Coli) intramuscularly at 0, 1, 6 month.

Participants would receive 3 doses of Recombinant Hepatitis E Vaccine (Escherichia Coli) intramuscularly at 0, 1, 6 month.

Trial Locations (1)

224200

Dongtai City Center for Disease Control and Prevention, Dongtai

All Listed Sponsors
collaborator

Jiangsu Province Centers for Disease Control and Prevention

NETWORK

lead

Xiamen Innovax Biotech Co., Ltd

INDUSTRY

NCT03365921 - A Phase Ⅳ Clinical Trial of the Recombinant Hepatitis E Vaccine (Escherichia Coli)(the Lot Consistency Trial) | Biotech Hunter | Biotech Hunter